Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Public ClinicalTrials.gov record NCT02071862. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Ph1 Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination With Standard Chemotherapy in Patients With Advanced and/or Treatment-Refractory Solid Tumors
Study identification
- NCT ID
- NCT02071862
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Calithera Biosciences, Inc
- Industry
- Enrollment
- 210 participants
Conditions and interventions
Conditions
- Solid Tumors
- Triple-Negative Breast Cancer
- Non Small Cell Lung Cancer
- Renal Cell Carcinoma
- Mesothelioma
- Fumarate Hydratase (FH)-Deficient Tumors
- Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST)
- Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors
- Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations
- Tumors Harboring Amplifications in the cMyc Gene
Interventions
- CB-839 Drug
- Pac-CB Drug
- CBE Drug
- CB-Erl Drug
- CBD Drug
- CB-Cabo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2014
- Primary completion
- Feb 28, 2019
- Completion
- Feb 28, 2019
- Last update posted
- Jul 19, 2022
2014 – 2019
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco | California | 94143 | — |
| Stanford University Medical Center | Stanford | California | 94305 | — |
| Florida Cancer Specialists | Sarasota | Florida | 34232 | — |
| Winship Cancer Institute of Emory School of Medicine | Atlanta | Georgia | 30322 | — |
| NIH - NCI - Center for Cancer Research | Bethesda | Maryland | 20892 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| University of Pennsylvania, Abramson Cancer Center | Philadelphia | Pennsylvania | 19104 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37203 | — |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02071862, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 19, 2022 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02071862 live on ClinicalTrials.gov.